SOUTH SAN FRANCISCO, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Anesiva, Inc. announced today that John P. McLaughlin, the company's chief executive officer, will present at BioCentury's Newsmakers in the Biotech Industry Conference in New York City on September 6, 2007 at 10:30 a.m. EDT.
To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Anesiva and its Diverse Portfolio of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's portfolio, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.
Anesiva, Inc.CONTACT: Paul Goodson, Sr. Dir., Investor Relations of Anesiva, Inc.,+1-650-246-6898, investors@anesiva.com
Web site: http://www.anesiva.com/
